Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FINRA Short Interest of IPIX
Settlement Date: 9/15/2017
Current Short: 1,214,089
Previous Short: 1,220,108
Change: -6,019 (-0.49%)
Average Daily Volume: 215,861
Days to Cover: 5.62
0.92% of the outstanding shares were short.
http://otce.finra.org/ESI
According to the SEC, only 11,557 shares (0.009% of the OS) were failure-to-deliver as of August 31.
20170831|45782D100|IPIX|11557|INNOVATION PHARMACEU|0.70
https://www.sec.gov/data/foiadocsfailsdatahtm
If the call option is .70, you still lose 100% of the option purchase price, .70. If the option is for 2.50, then you need 3.20 plus fees to make any money. Anything lower is a loss. Anything below 2.50 plus fees is a 100% loss.
If you buy a share you buy the share price. You could lose 100 percent. If you buy a call option you don't have to purchase. You can simply lose the premium if you want. Risk is less.
not on any board that ive seen
Well stated. I was reacting to the more general “option” statement.
You have no obligation to buy anything further with either.
Opinions go better with some reason and rationality.
Yes buy the buyer isn't obligated to actually purchase. So downside isn't as steep.
Well this so called risky option is why 'they' won't squeeeze it any lower that 70 cents other than paint the horrible Prurisol picture but the B platform is going to so overshadow the so-called P bomb that it won't even be funny. I am sure that there are some posters here that know this, but they want to keep the P boogey man alive so bad that they have you hearing 'ITS ALIVE ITS ALIVE ITS ALIVE!!!!!! imo I have seen better knock off edward scissor hand flicks
all imo
Their point is that at such a "low" valuation (which is admittedly a subjective judgement), the majority of the value in a share of IPIX is in its potential for upside appreciation, with no intrinsic (ie, book or salvage) value. This is much like the payoff profile of a call option. And since it is an equity share and not a call option contract, it has no (or put another way: indefinite) expiration.
So buying an IPIX share is like owning a call option in terms of high payoff potential but without the decay of an expiry date. As long as the company can stay funded, you have no expiration and you retain a potential for payoff. It's an attractive prospect, worth risking some capital on. The only decay is in our share of the payoff as the company issues more shares to fund itself.
FINRA short sales of IPIX
20171006|IPIX|29556|0|155170|O
19% of today's volume was short sales!
Go IPIX!!!
http://regsho.finra.org/FORFshvol20171006.txt
Options are a wasting asset often worthless on expiration. How can IPIX be more risky?
As risky as an option. Options are a sweetener for large share purchases, taking on senior positions, among other things. Options often expire becoming worthless, among other things.
More risky than an option.
Yes a perpetual option
Options... a good word since the share price is low enough to make it akin to an options purchase without the expiration date. ;)
In Reply to 'groton68'
Options. And we shouldn’t have to wait long
Options. And we shouldn’t have to wait long
OM will soon to be a billion dollar market and it's mostly untapped with just 5% of patients being prescribed for treatments. If top-line result shows 50% or higher prevention in severe OM, the FDA should grant BTD. A BTD designation would increase the odds of approval and decrease the time to approval. Why BPs won't be interested in an oral rinse drug which could dominate a billion dollar market?
The SP reached $1.08 after the very encouraging interim analysis. One week down and three more to go. Tick tock...
Yes, B-OM can fall into oncology, but, it can just as easily fall into the IBD camp.
That's why I'm delighted to see the Aspire deal. It gives them the freedom to take the right deal instead of simply the first one.
I'm still in agreement with groton68 that the entire brilacidin platform goes to one pharma. But, isn't it great to see the many directions the company can go in?!?!
In Reply to 'biodoc'
groton68,one BP partner for the entire Brilacidin platform certainly makes sense. Also consider that B-OM is (1) a unique formulation that is easily separated from the rest of the Brilacidin platform and (2) falls within Oncology. I'd suggest that an oncology focused pharma could do a clean deal for B-OM and K. Deals across multiple drug company divisions within a BP could take a lot longer than one or two products within a single large division.
IPIX will,imo, have a range of options moving forward and the resources to move the pipeline forward until the right deal is penned.
groton68,one BP partner for the entire Brilacidin platform certainly makes sense. Also consider that B-OM is (1) a unique formulation that is easily separated from the rest of the Brilacidin platform and (2) falls within Oncology. I'd suggest that an oncology focused pharma could do a clean deal for B-OM and K. Deals across multiple drug company divisions within a BP could take a lot longer than one or two products within a single large division.
IPIX will,imo, have a range of options moving forward and the resources to move the pipeline forward until the right deal is penned.
I'm surprised to hear a "long and strong" shareholder critizing the CEO.
OM will be YUUGGGEEEEE. Can't wait for those results. Shorts are going to get roasted.
Agreed... and, that's why I bought a bit more today.
In Reply to 'frrol'
I think you're right about results. I suspect biotech traders are going to start piling in as we approach early November. The next four months are momentous.
That was already explained many times. Just look through the posts.
P is more promising than ever. Shareholders will make mega bucks on P.
Echo agree, so why hasn't he released the interim results as he said he would??
JTORRENCE
The test results power over other information.
Echo20
Wasn't P always the wild card? I don't believe IPIX knows the results of P. If Leo was convinced he could get more funding, then why not wait until full results. What's the harm?
P was so promising to cancel interim and tap Aspire for 2 more years? OM it is to save this investment. K/P both fading dreams.
...will see shorty...
The shorts are running scared or the FACTS
Innovation Pharmaceuticals Completes Full Patient Enrollment in Phase 2b Study of Prurisol for the Oral Treatment of Psoriasis
Prurisol
BEVERLY, Mass., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that it has met the goal of 189 patients enrolled in its ongoingPhase 2b clinical study of Prurisol for the treatment of moderate-to-severe psoriasis. The final number of patients will be up to 199, including those awaiting final screening test results through the end of this week (September 1). Based upon the protocol for 12 weeks of Prurisol treatment and additional patient follow-up for 4 weeks, the study is expected to be completed in Q4 2017, with results to follow thereafter. Prurisol is being developed as a novel, non-biologic, orally-delivered psoriasis drug candidate.
Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals, commented, “The anticipated completion of the Prurisol trial in 2017, in combination with the expected Q4 completion of the Phase 2 trial of Brilacidin-OM for preventing and treating oral mucositis in chemoradiation patients, are significant milestones for the Company and its shareholders. There is a large need in psoriasis treatment for novel therapies, particularly those that are non-biologic and orally-dosed, and which can provide a safe, early, and sustained control of this common and debilitating skin disease. Regarding Brilacidin-OM for Head and Neck Cancer patients being treated with chemoradiation, presently there is no FDA approved drug for preventing severe oral mucositis, a very painful and debilitating disease.”
Study Overview
The randomized, double-blind, parallel-group and placebo-controlled study (see NCT02949388) increases the total daily oral dosing of Prurisol from a previous high of 200 mg, which earlier was shown to be well-tolerated and demonstrated early efficacy, to include oral Prurisol 300 mg per day, oral Prurisol 400 mg per day, and placebo (3:1:3 randomization). Enrolling, in total, approximately 189 patients with moderate-to-severe chronic plaque psoriasis, treatment duration is 12 weeks. Efficacy is being evaluated using the Psoriasis Area and Severity Index (PASI). Innovation Pharmaceuticals believes now is an opportune time to develop an oral treatment for psoriasis. Currently approved treatments, including injectable biologics, are limited, with many options costly, not easily administered, associated with undesirable side effects and/or diminishing effectiveness over time. A novel psoriasis drug, particularly one that is oral, safe and effective, which could expand patient and physician choices for treatment, likely would command significant market value.
http://www.ipharminc.com/press-release/2017/8/28/innovation-pharmaceuticals-completes-full-patient-enrollment-in-phase-2b-study-of-prurisol-for-the-oral-treatment-of-psoriasis
Good luck and GOD bless,
George
George yada yada yada, not giving interim up dates on "P" AS HE SAID HE WOULD THROWS UP A BIG RED FLAG NO MATTER HOW YOU LOOK AT IT. Now we have to wait till the end of year. Seems he is just buying time and hoping final data on "P" IS BETTER than the interim data. Also he's betting on "B" to be the headliner in the next few months, thus diverting attention away from "P" less than stellar results. JMO, will see shortly , unless Leo drops another bomb and pushes the whole ball of wax into next year..
Maxdud
Junk is turned into gold on this stock.
Echo20
.60s next week as Leo runs to the hills. Only so long can you convince a few people to keep buying. OM won't save 2017...
Georgejji
Which pharma will go first?
Echo20
Think about this: The current Prurisol trial will have at least 108 subjects taking Prurisol twice per day (at least 81 taking 150 mg twice per day and at least 27 taking 200 mg twice per day) at least 81 subjects will be taking a placebo twice per day.
See below, since 55% of subjects taking 100 mg twice per day and strictly adhering to the protocol achieved “clear” (0) or “almost clear” (1) in IGA, and since at least 108 subjects will be taking at least 150 mg twice per day, what percentage of the subjects in the current Phase 2b trial will achieved “clear” (0) or “almost clear” (1) in IGA? 82%
In the previous Prurisol trial
(200 mg group)
At Week 12: 42.8% subjects (ITT) [and 55.0% subjects (PP)] achieved “clear” (0) or “almost clear” (1) in IGA
https://static1.squarespace.com/static/5715352e20c647639137f992/t/5865318920099e2bc425d577/1483026833173/Cellceutix_Corporate_Slide+Deck_DERMATOLOGY_November+2016+Website+Vers.pdf
Good luck and GOD bless,
George
When will this stock start to move? This is getting old!
Love your idea. Only problem is flush with cash. Probably won’t give stock
I am hoping for a merger acquisition of IPIX with a big bio-pharma company with its stock that will give IPIX all the necessary tools to accomplish everthing in its first class drug arsenal candidates of the :» PRURISOL, BRILACIDIN & KEVETRIN .....imho,tryz
Some hints:
1- PoC: xyz company Oncology also conducts “Proof of Concept” trials, which are a mixture of Phase I and II studies. These small-scale studies help give us an early read on a drug’s safety and efficacy to find and advance the most promising drug candidates.
2- xyz company well involved in the P53 trials
GO IPIX...
PUT YOUR STOCK UP FOR SALE, IF YOU TRULY HAVE ANY AND SEE WHAT HAPPENS! LMBO
I agree. Trial results will be a surprise.
I posed a question to Art some time ago. I said wouldn’t it make the most sense to just have one partner with the whole Brilacidin platform. He answered yes.
We discussed the advertising issue and off label uses. It would be difficult to have multiple partners.
Remember he agreed to”make the most sense”. Nothing definite
What makes you believe that?
I believe a big surprise is in the making IMHO.
GO IPIX....
Posting history is a tell. OM is a unmet medical need. Brilacidin has the potential for standard of care use. Total 19 patients in interim report. Only 2 out of 9 patients in the Brilacidin (active arm) came down with severe OM Grade3 while 7 out of 10 in the placebo arm came down with severe OM.
Primary Efficacy Results Incidence of Severe OM (WHO Grade ≥ 3)
• Active Arm (Brilacidin): 2 of 9 patients (22.2 percent)
• Control Arm (Placebo): 7 of 10 patients (70 percent)
I think you're right about results. I suspect biotech traders are going to start piling in as we approach early November. The next four months are momentous.
Brilacidin for Oral Mucositis is unlikely to be spun off on its own. But, it will be interesting to watch how this all pans out. You could easily be correct.
Either way, the topline is likely to be in line with the spectacular interim results. I look forward to seeing them. ;)
In Reply to 'LilBigKahuna'
I don’t think Phase 3 can be skipped, though I hope the same. But, I do think B-OM will be licensed independently of the B platform since it is an oral rinse. That can easily come in the next quarter or two and for a very large upfront payment.
The reality is, most people aren't obsessed with every short term share price tick, and most people aren't looking to jump to every possible negative conclusion based on those short term ticks.
Continually insulting management based on short term share price moves doesn't make a lot of sense, in my opinion, unless a person is trying to day trade this stock, and attempting to affect share price with FUD.
I think he and team know what they are about to get. So why make waves and get people all excited. Silence is golden when you have pocket aces.
When he lays them down!!! BOOM!
ATLEAST that is what I believe.
Followers
|
976
|
Posters
|
|
Posts (Today)
|
10
|
Posts (Total)
|
403544
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |